The present application relates to compounds of formula (I) or a pharmaceutically acceptable derivative thereof; wherein X, R
1
, R
2
, and R
3
are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.
[EN] INDOLE COMPOUNDS<br/>[FR] COMPOSÉS À BASE D'INDOLE
申请人:GLAXO GROUP LTD
公开号:WO2008006790A1
公开(公告)日:2008-01-17
[EN] Compounds of formula (I) or a pharmaceutically acceptable derivative thereof; (formula I) wherein X, R1,R2, and R3are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine. [FR] La présente invention concerne des composés de formule (I) ou un dérivé de ceux-ci acceptable sur le plan pharmaceutique; dans la formule (I), X, R1, R2 et R3sont tels que définis dans le mémoire descriptif; un procédé de préparation desdits composés; des compositions pharmaceutiques comprenant lesdits composés; et l'utilisation desdits composés en médecine.
Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping
作者:Adrian Hall、Andy Billinton、Susan H. Brown、Anita Chowdhury、Gerard M.P. Giblin、Paul Goldsmith、David N. Hurst、Alan Naylor、Sadhana Patel、Tiziana Scoccitti、Pamela J. Theobald
DOI:10.1016/j.bmcl.2008.03.018
日期:2008.4
We describe the medicinal chemistry approach that generated a novel indole series of EP1 receptor antagonists. The SAR of this new template was evaluated and culminated in the identification of compound 12g which demonstrated in vivo efficacy in a preclinical model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.